期刊
CURRENT OPINION IN BIOTECHNOLOGY
卷 34, 期 -, 页码 225-231出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.copbio.2015.03.016
关键词
-
资金
- NIH Director's Transformative Research Award [HL117326]
- NHLBI [HL113468]
Injectable nanomaterials have been designed for the treatment of myocardial infarction, particularly during the acute stages of inflammation and injury. Among these strategies, injectable nanofibrous hydrogel networks or nanoparticle complexes may be delivered alone or with a therapeutic to improve heart function. Intramyocardial delivery of these materials localizes treatments to the site of injury. As an alternative, nanoparticles may be delivered intravenously, which provides the ultimate minimally invasive approach. These systems take advantage of the leaky vasculature after myocardial infarction, and may be designed to specifically target the injured region. The translational applicability of both intramyocardial and intravenous applications may provide safe and effective solutions upon optimizing the timing of the treatments and biodistribution.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据